Leqem­bi au­tho­riza­tion in EU is de­layed for pro­ce­dur­al is­sues

The EU re­view of Ei­sai’s Alzheimer’s drug lecanemab was de­layed this week be­cause of a pro­ce­dur­al is­sue at the Eu­ro­pean Med­i­cines Agency.

On Fri­day, Ei­sai said that a March 19 ques­tion-and-an­swer ses­sion on lecanemab at the Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) didn’t end up hap­pen­ing be­cause of a sep­a­rate le­gal is­sue that came days be­fore.

The de­lay is re­lat­ed to a court case be­tween D&A Phar­ma and the EMA. The Court of Jus­tice of the Eu­ro­pean Union’s rul­ing on the case from March 14 has “im­pli­ca­tions on EMA’s pol­i­cy on the han­dling of com­pet­ing in­ter­ests of ex­perts” in sci­en­tif­ic ad­vi­so­ry groups that pro­vide ad­vice to help eval­u­ate drugs, ac­cord­ing to Ei­sai.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER